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Genetic Variation in WNT9B Increases
Relapse Hazard in Multiple Sclerosis
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Klara Mallants, BSc,1,2 Friederike Held, MD,3 Lilian Aly, MD,3 Bruce V. Taylor, MD, PhD,4
Bernhard Hemmer, MD, PhD ,3,5 Bénédicte Dubois, MD, PhD,1,2,6 and An Goris, PhD 1,2
Objective: Many multiple sclerosis (MS) genetic susceptibility variants have been identified, but understanding disease
heterogeneity remains a key challenge. Relapses are a core feature of MS and a common primary outcome of clinical
trials, with prevention of relapses benefiting patients immediately and potentially limiting long-term disability accrual.
We aim to identify genetic variation associated with relapse hazard in MS by analyzing the largest study population
to date.
Methods: We performed a genomewide association study (GWAS) in a discovery cohort and investigated the geno-
mewide significant variants in a replication cohort. Combining both cohorts, we captured a total of 2,231 relapses
occurring before the start of any immunomodulatory treatment in 991 patients. For assessing time to relapse, we
applied a survival analysis utilizing Cox proportional hazards models. We also investigated the association between MS
genetic risk scores and relapse hazard and performed a gene ontology pathway analysis.
Results: The low-frequency genetic variant rs11871306 within WNT9B reached genomewide significance in predicting
relapse hazard and replicated (meta-analysis hazard ratio (HR) = 2.15, 95% confidence interval (CI) = 1.70–2.78,
p = 2.07 × 10−10). A pathway analysis identified an association of the pathway “response to vitamin D” with relapse
hazard (p = 4.33 × 10−6). The MS genetic risk scores, however, were not associated with relapse hazard.
Interpretation: Genetic factors underlying disease heterogeneity differ from variants associated with MS susceptibility.
Our findings imply that genetic variation within the Wnt signaling and vitamin D pathways contributes to differences in
relapse occurrence. The present study highlights these cross-talking pathways as potential modulators of MS disease
activity.
ANN NEUROL 2021;89:884–894
Multiple sclerosis (MS) is an autoimmune disease ofthe central nervous system (CNS). Despite progress
in identifying genetic variants associated with disease
susceptibility,1–4 the genetic drivers of disease severity and
heterogeneity in MS remain largely unknown. Relapses
are a key feature of relapsing remitting MS and patients
with a higher relapse rate have, at the group level, a more
severe disease course than patients with a lower relapse
rate.5 Preventing relapses benefits patients immediately
and is a common primary outcome measure in clinical tri-
als testing the efficacy of MS disease-modifying drugs.5 To
our knowledge, only one genomewide association study
(GWAS) for relapse risk has been performed previously,
reporting an association of genetic variants in the gene
LRP2 with relapse risk.6 This finding has been replicated in
a larger, independent cohort.7 Similar to the early days of
disease susceptibility GWASs, the identification of genetic
factors controlling disease heterogeneity is still in the initial
discovery phase, with novel and strong associations emerg-
ing from these studies.6,8 We performed a within-cases
GWAS for relapse hazard in a Belgian cohort, the largest
study population to date, with extensive genomewide
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coverage. For the first time, both common (>5%) and less
frequent (2–5%) variants were analyzed. Replication was
conducted in an independent, large German cohort of the
Technical University of Munich (TUM).
Materials and Methods
Discovery Phase
Study Population. Patients with MS fulfilled McDonald
diagnostic criteria 20179 and were recruited at the Depart-
ment of Neurology of the University Hospitals Leuven
upon providing written informed consent. The study was
approved by the Ethics Committee of the University Hos-
pitals Leuven (S60222). Clinical data, including relapse
and treatment history, were collected during clinical
follow-up by the same treating clinician (author B.D.).
Relapse was defined as the patient reported symptoms or
objectively observed signs typical of an acute inflammatory
demyelinating event in the CNS with a duration of at
least 24 hours, in the absence of fever or infection,
according to the 2017 McDonald criteria.9 Onset was
defined as the occurrence of first symptoms. A total of
506 patients with bout-onset MS with a median duration
of 4 years between disease onset and either the start of any
immunomodulatory treatment or the end of follow-up in
untreated patients were included. A description of the
study cohort is provided in Table 1.
Genotyping. Participants of this study were genotyped
for 700,078 variants using the Infinium HTS assay on
Illumina Global Screening Array BeadChips (version 1.0)
in 2 batches as part of genotyping of a larger cohort of
individuals, including participants of a companion study
published previously10 (batch 1 = 216 cases, 503 controls;
and batch 2 = 477 cases, 96 controls). Genotype calling
was conducted in GenomeStudio version 2011.1.
Genotype Quality Control. Genotype quality control
(QC) was performed jointly for all individuals. Sample
and variant QC were performed with PLINK version
1.09b5.4,11 as described previously,10 and following
guidelines from Anderson CA et al.12 For the individual-
level QC, a subset of common, high-quality variants with
a minor allele frequency (MAF) ≥5%, a genotyping suc-
cess rate ≥98% and a Hardy–Weinberg equilibrium
(HWE) test p > 10−6 was used. In total, 14 individuals
who showed either a genotype call rate <98% or excess
heterozygosity (>3 standard deviations from the sample
mean) were removed. The mean homozygosity rate across
X chromosome markers was calculated to exclude individ-
uals with discordant sex information (n = 9). The biologi-
cal relationship of all individuals was verified based on a
pairwise identity by descent (IBD) estimate, and duplicate
(n = 11) or related (PI-HAT >0.1875) individuals
(n = 12) were removed. For each pair showing cryptic
relatedness, the individual with the lower genotyping call
rate was removed from further analysis or, for MS cases,
the individuals with the shortest follow-up or the least
characterized. Genetic ancestry multidimensional scaling
(MDS) components were calculated and plotted combined
with the 1,000 Genomes project phase I reference panel13
to identify individuals with ancestry different from the
European cluster (n = 12). For both IBD and MDS ana-
lyses, regions of extended linkage disequilibrium
(LD)12,14,15 were removed, and the dataset was pruned so
that no pair of single nucleotide polymorphisms (SNPs)
within a given window of 50 kb was correlated (ie, LD
r2 > 0.2). A total of 660 MS cases and 574 controls
remained after sample QC.
Variant-level QC was performed in the cleaned
dataset. Alleles were aligned to the National Center for
Biotechnology Information (NCBI) build 37 forward
strand alleles to match the 1,000 Genomes phase III ver-
sion 5 imputation haplotype reference panel. Variants
with an MAF <1%, a call rate <98% for common (MAF
>5%) or <99% for less frequent variants (1% ≤ MAF
≤5%), or a significant deviation from the HWE (HWE
test p < 10-6) were excluded (n = 197,497). In addition,
the following variants were excluded: A/T and G/C SNPs
with an MAF >0.4 (n = 407), SNPs missing in the 1,000
Genomes reference panel (n = 229), sex-chromosome and
mitochondrial SNPs (n = 876), indels (n = 108), SNPs
with non-matching alleles in 1,000 Genomes (n = 495),
duplicate SNPs (n = 256), and SNPs showing an allele fre-
quency difference >0.2 with the reference panel (n = 859).
Finally, variants with batch effects were removed (n = 61).
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Baseline = follow-up time from disease onset prior to any treatment;
IQR = interquartile range; N = number of individuals.
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For this purpose, MS cases and controls were extracted
from the cleaned sample set, with the batch number in
which they were genotyped as the phenotype. For both
MS cases and control individuals, a logistic regression
analysis for the genotyping batch was performed. Outlier
genetic variants were defined as reaching p < 0.05
(Bonferroni adjusted p value for the number of SNPs) in
cases and/or controls. A total of 4 individuals were gen-
otyped in both batch 1 and batch 2. Both batches were
merged with PLINK with a report of mismatching non-
missing calls. Outliers were defined as variants appearing
different between 2 batches in more than one sample. A
total of 487,395 SNPs remained after QC.
Genotype Imputation. Genotypes were pre-phased with
SHAPEIT2 (version 2.12)16 using the 1,000 Genomes
phase III EUR reference panel (October 2014). Imputa-
tion was performed using IMPUTE version 2.017,18 and
all 1,000 Genomes populations in approximately 5 Mb
chunks (http://dougspeed.com/imputation-regions/). The
INFO metric reflects the SNP imputation accuracy. Any
missing genotypes for directly genotyped variants
(INFO = 1) were filled in with the -pgs_miss parameter.
The HWE test p value was obtained using QCTOOL ver-
sion 2. Variants with an imputation INFO metric ≥0.9,
an MAF ≥2% (corresponding to an expected minimum of
20 effect alleles), and an HWE test p > 1 × 10−6 were
retained for GWAS. The final dataset contained 7,344,935
autosomal variants, including 6,118,705 common (MAF
>5%) and 1,226,230 less common variants (MAF 2–5%).
Genotype probabilities were converted into minor allele
dosages. When <6 individuals showed a dosage >1.5 for a
specific variant, all dosages >1 were set to 1. Thereby, we
used dominant inheritance models for low frequency vari-
ants, comparing carriers with noncarriers. All remaining
variants were analyzed using additive models.
Top-associated SNPs that were directly genotyped
were validated by inspection of cluster plots. For imputed
SNPs, the discordance rate of the nonreference allele was
assessed via Sanger sequencing and TaqMan genotyping.
For the low frequency SNP rs11871306, genotyping of
imputed calls in the entire discovery cohort was validated
using a TaqMan assay (C_1139290_10; Life Technolo-
gies) and Sanger sequencing (Forward primer: 50-
GGGTTATGCACACTCACCCA-30, Reverse primer: 50-
GCCAGGGCAAAAGCCTTAAC-30).
GWAS Analysis. The association analysis of genetic vari-
ants coded as minor allele dosages and the time to relapses
were assessed using a Cox proportional hazards model cal-
culated with the coxph function in the “survival” package
in R version 3.4.2. Only relapses at baseline (before
treatment initiation) were included. The disease onset was
defined as the first relapse, and any subsequent relapse was
considered as an event. Each relapse resets the time to
zero, as described previously.6 As censor, either the start of
immunomodulatory treatment or – for untreated patients
– the end of follow-up was considered. The different time
periods were analyzed separately and adjustment of stan-
dard errors (SEs) for clusters of correlated observations
(relapses within the same individual) was performed by
applying the cluster function in the Cox proportional haz-
ards model and by calculating robust SEs. The hazard
ratio (HR) was estimated by considering each time at
which an event occurred; the overall HR across the base-
line duration was averaged over the event times.19 Model
significance was assessed using the Wald test, not assum-
ing independence of observations within clusters. Like-
wise, time to treatment initiation, based on clinical
assessment by the same treating neurologist, was analyzed
with the Cox proportional hazards model, using the end
of follow-up as the censor. We confirmed the proportional
hazards assumption with the Schoenfeld residuals test. For
plots of the predicted survival curve (time to relapse), the
Cox proportional hazards model was fitted using geno-
types determined via TaqMan and Sanger sequencing. To
estimate the median time to relapse, corresponding to the
time at which 50% of the individuals (carriers vs noncar-
riers of the rs11871306*C allele) remain relapse-free after
the previous event, we passed the fitted Cox proportional
hazards model to the survfit function in R.
Genetic MDS ancestry components were calculated
in PLINK version 1.09b6.9, based on the set of variants
with an MAF ≥5%, genotyping success rate ≥98% and
HWE test p > 10−6 and after removing regions of
extended LD12,14,15 and dataset pruning so that no pair of
SNPs within a given window of 50 kb was correlated (ie,
LD r2 > 0.2). As eigenvalues were <2.0, the primary analy-
sis was performed without MDS components as
covariates.20 Sensitivity analyses were performed for the
replicated genetic variants, including age at onset, sex, and
the first 8 ancestry MDS components as covariates.
The Manhattan plot was created using the “CMplot”
package in R version 3.6.1. Regional association plots were
generated using the LocusZoom21 webtool. Independent
genomewide significant (p < 5 × 10−8) SNPs were defined
as having an r2 < 0.1 in the 1,000 Genomes phase III
EUR super population in LDmatrix (https://ldlink.nci.nih.
gov/?tab=ldmatrix). Functional annotation was done using
RegulomeDB version 1.122 and HaploReg version 4.1.23
MS Genetic Risk Score. The latest MS genomic map
includes 200 independent autosomal susceptibility variants
outside the major histocompatibility complex (MHC), of
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which 138 are primary, independent effects, as well as
31 statistically independent variants within the MHC
region.2 In a primary analysis, the non-MHC MS genetic
risk score was calculated starting from the 138, primary,
independent non-MHC effects. Strand-ambiguous SNPs
with an effect allele frequency between 40% and 60%
were replaced by non-strand-ambiguous proxy SNPs
showing r2 > 0.9 with the published lead variants. A total
of 135 non-MHC SNPs (including 5 proxy SNPs show-
ing r2 > 0.9 with the published lead variants) were present
in the imputed genetic data and hence included in the
MS genetic risk score (Table S1). In addition, 22 MHC
risk variants were present in the imputed genetic data and
included in the MHC MS genetic risk score (Table S2).
In a secondary analysis, we included both primary and
secondary independent effects in the non-MHC region.
The secondary effects emerged from conditional modeling
in the original susceptibility analysis.2 The genetic risk
score was weighted using the marginal odds ratios. A total
of 195 non-MHC SNPs were included in our secondary
analysis (including 6 proxy SNPs showing r2 > 0.9 with
the published lead variants; Table S3).
Classical human leukocyte antigen (HLA) alleles,
amino acid polymorphisms, and SNPs in the MHC
region were imputed with SNP2HLA version 1.0.3 and
the T1DGC reference panel (build 37).24 To investigate a
potential association between the burden of MS suscepti-
bility variants and relapse hazard, weighted MS genetic
risk scores for the non-MHC SNPs and MHC risk vari-
ants were calculated using PRSice version 2.3.1.e,25
assuming an additive genetic model. The association
between the weighted MS genetic risk scores and time to
relapses was assessed using a Cox proportional hazards
model, as described above.
Gene Ontology Pathway Analysis. Genetic variants were
assigned to their corresponding genes based on their posi-
tion according to the NCBI 37.3 (hg19) build with
MAGMA version 1.07. For each gene, a p value was cal-
culated using a SNP-wise multi model (ie, by integrating
the p values for the mean and top SNP association within
a gene into an aggregated p value for that gene). Subse-
quently, a competitive gene-set analysis was performed to
test whether the mean association with relapse hazard of
genes in a specific gene set is greater than that of genes
not in the gene set while conditioning on gene size, gene
density, inverse minor allele count, log (gene size), log
(gene density), and log (inverse minor allele count)
according to standard settings. This analysis was repeated
for each of the 10,181 Gene Ontology gene sets from the
Molecular Signatures Database website (MSigDB, release
7.1, March 2020). We applied a Bonferroni correction for
the number of gene sets tested (α = 0.05/10,181 =
4.91 × 10−6).
Replication Phase
Study Population. For replication, 485 patients with
relapsing–remitting MS were analyzed. This cohort
included all patients with available genotype and longitu-
dinal relapse data diagnosed after 2010 at the Klinikum
rechts der Isar of the Technical University of Munich.
Diagnoses and the definition of relapses were based on the
2017 McDonald criteria.9 Among these 485 patients,
819 relapses were captured over a median baseline dura-
tion of 0.5 years before receiving any treatment (see
Table 1). Written informed consent was obtained from all
patients according to the Declaration of Helsinki and sam-
ples were collected with ethical approval of the Klinikum
rechts der Isar.
Genotyping, QC, and Imputation. SNPs were genotyped
using Illumina OmniExpress BeadChips. QC was con-
ducted using PLINK version 1.90b7, as described previ-
ously.4 QC and imputation were carried out within a
larger dataset of patients with MS. In brief, individuals
were removed if fulfilling any of the following criteria: sex
mismatches; genotyping rate <98%; cryptic relatedness
>1/8; genetic outliers (distance in the first 8 MDS compo-
nents of the identity-by-state matrix >4 standard devia-
tions); a significant deviation in autosomal heterozygosity
from the mean (>4.4 standard deviations); and X-
chromosomal heterozygosity ≤0.2. Variants were excluded
according to the following criteria: call rate <98%; MAF
<1%; HWE test p < 1 × 10-6; A/T and G/C variants; var-
iants not present in the 1,000 Genomes phase III refer-
ence panel. Genotype data were imputed to the 1,000
Genomes phase III reference panel using SHAPEIT216
and IMPUTE2.17,18 The resulting dataset contained
8,964,526 high-quality variants with an MAF ≥0.01 and
INFO ≥0.8.
Association Analysis. A total of 8 SNPs reaching geno-
mewide significance in the discovery cohort were present
in the replication cohort. For these SNPs, association anal-
ysis between the minor allele dosages and time to relapses
was assessed using the Cox proportional hazards model,
including the first 8 MDS components as covariates.
Meta-Analysis
A variant was considered as replicated if the two-sided p in the
replication sample <0.006 (= 0.05/8 SNPs in replication phase)
with an effect in the same direction, and a meta-analysis
p < 5 × 10−8 using the inverse variance-weighted method and
the fixed-effects model in META version 1.7.
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Results
MS Genetic Risk Scores are not Associated With
Relapse Hazard
Among 506 Belgian patients with MS, 1,412 relapses were
captured over a median baseline duration of 4 years before
receiving any treatment (see Table 1). Neither the MS genetic
risk score consisting of 135 primary, independent SNPs out-
side the MHC region (HR = 0.95, 95% confidence interval
[CI] = 0.87–1.05, p = 0.33) nor the MHC genetic risk score
(HR = 1.01, 95% CI = 0.94–1.10, p = 0.76) was associated
with relapse hazard at baseline. Including both primary and
secondary independent SNPs outside the MHC region in the
MS genetic risk score, resulted in very similar findings
(HR = 0.95, 95% CI = 0.87–1.03, p = 0.24). Thus, genetic
variants conveying MS disease risk did not appear to be major
drivers of relapse hazard in our cohort, warranting geno-
mewide approaches.
Genomewide Association Study Identifies
rs11871306 as a Novel SNP Affecting Relapse
Hazard
We analyzed 7,344,935 SNPs with an MAF ≥2%, HWE
test p > 1 × 10−6, and INFO ≥0.9 after imputation and
QC, with the Manhattan plot shown in Figure 1. The geno-
mic inflation factor (λ) of the GWAS was 1.02, indicating no
inflation of test statistics. In this discovery stage GWAS,
10 independent loci passed the threshold for genomewide
significance (p < 5 × 10−8; Table 2). For imputed SNPs,
nonreference allele discordance rates (4–18%), calculated
based on direct genotyping and Sanger sequencing, were in
line with expectations, especially for low-frequency variants.26
Eight of the genomewide significant loci in the discov-
ery cohort were available and passed postimputation QC in
the replication cohort, capturing 819 relapses over a median
baseline duration of 0.5 years in 485 treatment-naïve
patients (see Tables 1 and 2). For the directly genotyped
variant rs11871306 on chromosome 17, the association
with relapse hazard replicated after Bonferroni correction for
multiple testing (p = 1.01 × 10−4). Sensitivity analyses indi-
cated that including covariates did not substantially alter the
results (Table S4) and that the Cox proportional hazards
assumption was fulfilled (Schoenfeld residual test p value for
discovery cohort = 0.27). In an inverse variance-weighted
fixed-effects meta-analysis using direct genotypes for both
the discovery and replication cohorts, variant rs11871306
was associated with relapse hazard with HR = 2.15, 95%
CI = 1.70–2.78, and p = 2.07 × 10−10 (Fig 2).
WNT9B rs11871306 Minor Allele Carriers Show
More Disease Activity
Depending on the isoform, rs11871306 is either located
in an intron or the 30 untranslated region (UTR) of the
gene Wnt family member 9B (WNT9B; Fig 3). The vari-
ant maps to a DNaseI hypersensitivity cluster identified in
FIGURE 1: Manhattan plot showing genomewide association results of the survival analysis for time to relapse in the discovery
phase. Each dot represents a genetic variant, with the x-axis depicting chromosomal position and the y-axis showing the
negative logarithm of the p value for an association with relapse hazard. The red line indicates the genomewide significance
threshold (p = 5 × 10−8).
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several cell types, including both immune and brain cells
from the ENCODE and Roadmap Epigenomics projects.
The minor allele C, with a frequency of 2% in European
but up to 29% in African populations, disrupts a binding
motif for the transcription factor c-Ets-1. The associated
region is located toward the telomeric end of a well-known
large 900 kb inversion (H1/H2), but is not in linkage dis-
equilibrium (LD) with SNPs (rs1800547 and rs9468) tag-
ging this inversion (r2 = 0.0003).27 Of note, in both the
discovery and replication phase of our study, rs11871306
was associated with relapse hazard but this variant is not
associated with MS susceptibility (OR = 1.01, p = 0.90) in
the most recent published MS risk GWAS.2
In both the discovery and replication cohorts, indi-
viduals carrying the minor rs11871306*C allele had a
shorter time to relapse compared with noncarriers (Fig 4).
The median time that patients remained relapse-free in
the discovery cohort was 0.95 years for carriers versus
2.22 years for noncarriers. In the replication cohort, indi-
viduals carrying the rs11871306*C allele similarly showed
a shorter time to relapse compared with noncarriers, with
a median time to relapse of 0.59 versus 2.00 years. A sec-
ondary analysis in the discovery cohort showed that
rs11871306*C carriers had received treatment earlier than
noncarriers (HR = 1.90, 95% CI = 1.16–3.10, p = 0.01),
based on standard clinical evaluation by the same treating
neurologist.
Pathway Analysis Implicates Vitamin D Response
in Susceptibility to Relapses
Using the discovery-stage GWAS summary statistics, a
gene-set analysis based on Gene Ontology pathways was
performed to further explore the underlying biology of
relapses. The only significant pathway after correction for
multiple testing was “Response to vitamin D” (GO:
0033280; uncorrected p = 4.33 × 10−6; Table 3). This
pathway is defined in Gene Ontology as “reflecting pro-
cesses that result in a change in state or activity of a cell or
an organism as a result of a vitamin D stimulus.” Other
pathways ranking among the top 10 results but not meet-
ing the Bonferroni correction threshold include response
to viruses and interferon-α secretion (see Table 3). Of
note, the biological process “Cell-cell signaling by WNT”
(GO: 0198738), including WNT9B, ranked at 210 of
10,181 (2.06%; Table S5).
Discussion
In the present study, we identified low-frequency variation
in the gene WNT9B to increase relapse hazard in MS
cases. Combining 2 longitudinal cohorts, capturing a total
of 2,231 relapses in 991 treatment-naïve individuals,
rs11871306, mapping to the WNT9B gene, reached geno-
mewide significance. Individuals carrying the minor allele
showed a more than doubled relapse hazard.
TABLE 2. Independent (r2 < 0.1) Genomewide Significant Associations With Relapse Hazard in the Discovery
Cohort
SNP CHR:POS A1 A2
Discovery cohort Replication cohort
HR SE P MAF INFO DISC HR SE P MAF INFO
rs139075191 2:183736241 G A 1.85 0.11 4.44 × 10−8 0.03 0.98 14 1.06 0.24 0.80 0.03 0.93
rs36084110 2:163160798 T C 2.58 0.13 7.72 × 10−14 0.02 0.91 5 1.22 0.24 0.41 0.03 0.89
8:1197491 8:1197491 C G 2.36 0.15 1.31 × 10−8 0.02 0.95 NA 0.57 0.33 0.09 0.02 0.92
rs79434188 12:33587295 A T 0.49 0.13 1.90 × 10−8 0.03 0.95 4 1.02 0.37 0.96 0.02 0.84
rs117185095 12:117089904 G T 2.58 0.16 1.23 × 10−9 0.02 1 NA NA NA NA NA NA
rs77836326 13:50601566 G A 0.52 0.12 1.42 × 10−8 0.03 1 NA 0.99 0.36 0.98 0.02 0.91
rs17817182 15:33716899 C A 2.00 0.13 4.85 × 10−8 0.03 1 NA NA NA NA NA NA
rs79719335 15:51835376 A G 2.13 0.14 4.04 × 10−8 0.02 0.94 18 1.43 0.24 0.14 0.02 0.94
rs76915261 17:774611 T C 2.00 0.13 2.85 × 10−8 0.03 1 NA 1.70 0.29 0.06 0.03 0.87
rs11871306 17:44954984 C T 2.08 0.17 3.37 × 10−8 0.02 0.97 10 2.53 0.24 1.01 × 10−4 0.02 1.00
All variants with an INFO value of 1 were genotyped.
A1 = minor allele (effect allele); A2 = major allele; CHR = chromosome; DISC = percentage of discordant non-reference alleles between direct
genotyping and imputation; HR = hazard ratio; INFO = imputation INFO metric; MAF = minor allele frequency; NA = not applicable/not available;
P = p-value; POS = position (hg19); SE = robust standard error.
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The protein Wnt-9b functions in the canonical
Wnt/β-catenin signaling pathway as a component of the
Wnt-Fzd-LRP5-LRP6 signaling complex. Wnt/β-catenin sig-
naling plays a critical role in nervous system development,
axonal guidance, and synapse formation.28 It has been impli-
cated in neuropsychiatric disorders, such as autism and
schizophrenia,28–30 and in neurodegenerative disorders, such
as Parkinson’s disease31 and Alzheimer’s disease.32
FIGURE 2: Forest plot of meta-analysis of rs11871306*C association with relapse hazard. The Cox proportional hazards model
was fitted with genotypes obtained by direct genotyping: genotypes obtained through TaqMan genotyping and Sanger
sequencing for the discovery cohort, and through genotyping array for the replication cohort. CI, confidence interval; HR, hazard
ratio.
FIGURE 3: Regional association plot of chromosome 17q21.32 with lead single nucleotide polymorphism (SNP) rs11871306
demonstrating an association with relapse hazard. Association results (primary y-axis) are shown for genetic variants with a minor
allele frequency (MAF) ≥2% and imputation INFO metric ≥0.9, along with recombination rates (secondary y-axis), for a 500 kb
region (250 kb region flanking the lead SNP rs11871306 (chr17:44954984 (hg19)). Each dot represents the -log10p value from
the survival analysis using the Cox proportional hazards model including baseline relapses before any immunomodulatory
treatment. Genetic variants are colored according their linkage disequilibrium (LD; r2) with the lead SNP using the 1,000
Genomes Phase III EUR superpopulation.
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In the mouse model Experimental Autoimmune
Encephalitis (EAE), the effects of the Wnt/β-catenin path-
way depend on the specific cell types in which the pathway
is active. Endothelial Wnt/β-catenin signaling protects
cerebrovascular integrity,33 and reduces immune cell infil-
tration by decreasing vascular cell adhesion molecule
(VCAM)-1 and Caveolin1 expression.34 Downregulation
of Wnt signaling in oligodendrocytes after white matter
injury may, on the other hand, support regenerative mye-
lination.35,36 Upregulation of the Wnt pathway in oligo-
dendrocyte precursor cells induces a negative feedback loop
involving production of the Wnt inhibitory factor (Wif1),
which may add to a disruption of the blood-brain bar-
rier.37 Overall, the Wnt/β-catenin pathway appears to have
FIGURE 4: Survival curves for time to relapse by rs11871306 genotype. (A) In the discovery cohort, individuals carrying the
rs11871306*C allele have a shorter time to relapse compared with noncarriers, with a median relapse-free interval of 0.95 versus
2.22 years. (B) In the replication cohort, individuals carrying the rs11871306*C allele have a shorter time to relapse compared
with noncarriers with a median relapse-free interval of 0.59 versus 2.00 years. Dotted lines represent 95% confidence intervals.
TABLE 3. Top-10 Gene Ontology Terms Enriched for Associations with Relapse Hazard
GO terms GO ID N GENES BETA SE p
Response to vitamin D GO:0033280 32 0.76 0.17 4.33 × 10−6
Detection of virus GO:0009597 6 1.53 0.37 1.55 × 10−5
Positive regulation of heterotypic cell–cell adhesion GO:0034116 16 0.93 0.23 2.79 × 10−5
αβ T-cell receptor complex GO:0042105 5 1.59 0.40 3.64 × 10−5
Origin recognition complex GO:0000808 9 0.86 0.22 3.89 × 10−5
Interferon-α secretion GO:0072642 9 1.17 0.30 4.59 × 10−5
Negative regulation of fibroblast migration GO:0010764 6 1.25 0.32 5.60 × 10−5
Presynaptic active zone cytoplasmic component GO:0098831 16 0.94 0.24 5.82 × 10−5
Regulation of cell chemotaxis to fibroblast growth factor GO:1904847 6 1.29 0.33 6.13 × 10−5
Positive regulation of mRNA processing GO:0050685 29 0.53 0.14 8.82 × 10−5
P values that passed Bonferroni correction (alpha = 0.05/10,181) are highlighted in bold font.
BETA = the regression coefficient of association with relapse hazard for gene sets in the GO pathway; GO = Gene Ontology; ID = identifier, N
GENES = number of genes in the data that are part of the GO pathway; P = p-value; SE = standard error.
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a beneficial effect on EAE: deletion of the Wnt co-
receptors LRP5 and LRP6 or of β-catenin in dendritic cells
exacerbates EAE disease severity,38 whereas β-catenin ago-
nist treatment of healthy mice before disease induction
results in a delayed EAE onset and reduced EAE severity.
Likewise, therapeutic activation of β-catenin after disease
induction reduces clinical severity of EAE and CNS
pathology.38
Data on the Wnt pathway in the context of human
MS are limited, but whole-blood RNA gene expression
analysis in cases and controls revealed an upregulation of
Wnt signaling in MS cases versus controls.39 Similarly,
upregulation of the Wnt pathway in MS lesions37 and
brain blood vessels34 has been observed. Our data now
add that genetic variation in the Wnt pathway contributes
to differences in relapse hazard between patients.
Following the GWAS identifying an association of a
variant in the WNT9B gene with relapse hazard, we con-
ducted a pathway-based association analysis. Pathways
ranking highly within the top 10 association results
included “detection of virus” and “Interferon-α secretion.”
As a role of viruses in triggering relapses and of type I
interferon in preventing relapses has been well
described,40,41 this finding supports the validity of our
analysis. Our pathway analysis identified vitamin D
response as significantly associated after the highly conser-
vative Bonferroni correction for multiple testing, given
that pathways were partially overlapping. Vitamin D is a
known immunomodulator, skewing cells of the adaptive
immune system toward a more tolerogenic status
in vitro.42 Increased levels of 25-hydroxyvitamin D (25
(OH)D) are associated with a decrease in relapses in MS
observational studies.43,44 In addition, the low-density
lipoprotein receptor-related protein 2 (LRP2), previously
associated with relapse hazard6,7 and in the discovery
cohort reaching HR = 1.17, 95% CI = 1.02–1.32, and
p = 0.02, is a transmembrane receptor that mediates
uptake and activation of 25(OH)D through endocytosis
in renal45 and mesenchymal stem cells.46 Crosstalk
between vitamin D and the Wnt pathway is suggested,
with the direction of effect depending on the biological
system. In cancer cells, vitamin D can act as an antagonist
of Wnt/β-catenin, but it may act as a co-activator in other
cell types, such as osteoblasts and keratinocytes.47 In mice,
maternal vitamin D deficiency led to lower levels of
Wnt3a, β-catenin, and the tight junction protein
claudin-1 and to a higher permeability in the offspring’s
intestinal epithelial barrier.48 This barrier shows similari-
ties with the blood–brain-barrier.49
Neither the WNT9B variant we report here nor the
previously identified LRP2 variant are associated with MS
susceptibility.2 The genetic risk burden is a more powerful
instrument than the analysis of single variants for dis-
tinguishing differences in susceptibility, and has previously
been associated with the presence of oligoclonal bands in
the cerebrospinal fluid.50 Our findings do not confirm the
previously reported trend for an association of the non-
MHC genetic risk burden with higher baseline relapse
rate,50 in line with other studies investigating the associa-
tion between weighted genetic MS risk scores and
relapses.51 Similarly, analyses for other diseases, such as
Crohn’s disease, emphasize the difference between suscep-
tibility and disease course heterogeneity after onset.52 Our
data suggest that the genetic basis for relapse hazard is dis-
tinct from genetic factors driving disease susceptibility.
However, larger studies are required to exclude a more
modest effect of MS-associated variants on relapse.
Our main association results point to the involve-
ment of less common variants (MAF 2–5%) in relapse
hazard with relatively large effect sizes. The previously
published GWAS investigating the association between
genetic variants and relapse hazard was limited to common
SNPs (MAF >5%).6 A second strength of the present
study is that we only included relapses before treatment to
prevent the confounding effect of treatment on relapse
hazard, as effective disease-modifying treatments reduce
relapse rates. In the pooled analysis, 991 individuals were
included, rendering this the largest study population to
date for relapse hazard in MS. However, to fully identify
the genetic architecture of relapse in MS, larger study
cohorts with even longer follow-up periods are required.
Limitations of our study include the higher complexity of
disease heterogeneity phenotypes compared with suscepti-
bility.53 However, all relapses in our discovery cohort were
registered by one expert clinician and our findings were
replicated in an independent replication cohort.
The HR of 2 observed in both cohorts in this study
indicates clinically meaningful differences, comparable to
primary outcome effect sizes expected in clinical trials.54 In
the discovery cohort, this translates in carriers of the minor
allele remaining relapse-free for a median duration of
1 year versus more than 2 years in noncarriers. The con-
verging impact of the Wnt and vitamin D pathways on
blood–brain barrier integrity and immune cell infiltration
provides an immediate parallel with existing efficacious
treatments. Blockade of VCAM-1 interactions with its cog-
nate lymphocyte ligand integrin α4 decreases immune cell
infiltration into the CNS and reduces the clinical severity
of EAE.55 This constitutes the basis for the MS disease
modifying treatment (DMT) natalizumab, which reduces
the rate of relapse by 68%56 and is regarded as a high effi-
cacy DMT, albeit with safety considerations.57
In conclusion, we have identified an association
between genetic variation in WNT9B and in the vitamin
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D pathway with relapse hazard. Further functional assess-
ment of the Wnt/β-catenin and vitamin D pathway in
MS disease activity is necessary to provide an improved
mechanistic understanding of the association underlying
patient-to-patient variation in relapse hazard, potentially
leading to improved opportunities for therapeutic
intervention.
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